Skip to content

Expanded Access to Mepsevii

Status
AVAILABLE
Phases
Unknown
Study type
Expanded Access
Source
ClinicalTrials.gov
Registry ID
NCT03775174
Enrollment
Unknown
Registered
2018-12-13
Start date
Unknown
Completion date
Unknown
Last updated
2026-07-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

MPS VII, Mucopolysaccharidosis VII, Sly Syndrome

Keywords

Expanded Access, Compassionate Use

Brief summary

Individual patient expanded access requests may be considered for patients who have no other treatment options

Detailed description

Expanded access may be available outside of the US in countries prior to approval by the local regulatory agencies. For full details, please visit the links provided below.

Interventions

DRUGMepsevii

Sponsors

Ultragenyx Pharmaceutical Inc
Lead SponsorINDUSTRY

Eligibility

Sex/Gender
ALL

Inclusion criteria

\-

Exclusion criteria

\-

Contacts

CONTACTEarly Access
EarlyAccess@ultragenyx.com

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jul 31, 2026